These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8565016)

  • 21. Metabolic syndrome X: a review.
    Timar O; Sestier F; Levy E
    Can J Cardiol; 2000 Jun; 16(6):779-89. PubMed ID: 10863169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of activated FXII in survivors of myocardial infarction--association with circulating risk factors and extent of coronary artery disease.
    Kohler HP; Carter AM; Stickland MH; Grant PJ
    Thromb Haemost; 1998 Jan; 79(1):14-8. PubMed ID: 9459314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors.
    De Pergola G; Pannacciulli N; Coviello M; Scarangella A; Di Roma P; Caringella M; Venneri MT; Quaranta M; Giorgino R
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):227-32. PubMed ID: 17400434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia.
    Flack JM; Sowers JR
    Am J Med; 1991 Jul; 91(1A):11S-21S. PubMed ID: 1867224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship between parameters of hemostasis and manifestations of the metabolic syndrome in men with mild and moderate hypertension].
    Ratnikova LA; Metel'skaia VA; Mamedov MN; Olfer'ev AM; Perova NV
    Ter Arkh; 2000; 72(9):13-6. PubMed ID: 11076408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperinsulinemia in patients with coronary heart disease in absence of overt risk factors.
    Ariza CR; Frati AC; Gómez G; Almazán A
    Arch Med Res; 1997; 28(1):115-9. PubMed ID: 9078598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of lipid and glycaemic abnormalities in hypertensive patients: a retrospective survey.
    Joglekar SJ; Nanivadekar AS
    Indian Heart J; 1996; 48(4):371-4. PubMed ID: 8908824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Coagulation factors, platelets and coronary heart disease].
    Rasi V; Salomaa V; Pekkanen J
    Duodecim; 1991; 107(15):1277-85. PubMed ID: 1365350
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators.
    Cushman M; Yanez D; Psaty BM; Fried LP; Heiss G; Lee M; Polak JF; Savage PJ; Tracy RP
    Am J Epidemiol; 1996 Apr; 143(7):665-76. PubMed ID: 8651228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic abnormalities in hypertension.
    Afonso LC; Edelson GW; Sowers JR
    Curr Opin Nephrol Hypertens; 1997 May; 6(3):219-23. PubMed ID: 9263663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet adhesiveness, plasma fibrinogen and factor 8 levels in diabetes mellitus.
    Mayne EE; Bridges JM; Weaver JA
    Diabetologia; 1970 Aug; 6(4):436-40. PubMed ID: 5452393
    [No Abstract]   [Full Text] [Related]  

  • 32. Dietary treatment of thrombogenic disorders related to the metabolic syndrome.
    Marckmann P
    Br J Nutr; 2000 Mar; 83 Suppl 1():S121-6. PubMed ID: 10889802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation between batches in clotting factor assays.
    North WR; Stirling Y; Meade TW
    Thromb Haemost; 1982 Dec; 48(3):274-6. PubMed ID: 6819647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genetics of atherothrombotic disorders: a clinician's view.
    Grant PJ
    J Thromb Haemost; 2003 Jul; 1(7):1381-90. PubMed ID: 12871271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinogen levels and pulmonary metastases in rats. Effect of tissue damage.
    Agostino D; Cliffton EE
    Arch Pathol; 1969 Feb; 87(2):141-5. PubMed ID: 5763619
    [No Abstract]   [Full Text] [Related]  

  • 36. [Established risk factors and complementary risk factors as additional parameters in evaluating the risk of cardiovascular diseases].
    Vrhovski D; Mestrić Z; Subić N; Surina B; Kranjcević S
    Lijec Vjesn; 1985; 107(11-12):481-4. PubMed ID: 4079647
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemostatic risk factors for coronary heart disease.
    Ridker PM; Hennekens CH
    Circulation; 1991 Mar; 83(3):1098-100. PubMed ID: 1999016
    [No Abstract]   [Full Text] [Related]  

  • 38. Haemostatic function and ischaemic heart disease.
    Meade TW
    Adv Exp Med Biol; 1984; 164():3-9. PubMed ID: 6421104
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chronobiology of fibrinogenemia and of Howell's time in normal, coronaropathic and hypertensive subjects].
    Petralito A; Mangiafico RA; Gibiino S; Cuffari MA; Miano MF; Marzella C; Fiore CE
    Boll Soc Ital Cardiol; 1981; 26(10):1331-4. PubMed ID: 7349162
    [No Abstract]   [Full Text] [Related]  

  • 40. [Lipid metabolism and insulin tolerance in chronic ischemic heart disease].
    Polishchuk II
    Vrach Delo; 1981 Apr; (4):74-6. PubMed ID: 7023048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.